CONTACT US
Home > Inhibitors/Agonists>Adenosine Deaminase> > Cladribine
Cladribine

Cladribine

  • CAT Number: I003531
  • CAS Number: 4291-63-8
  • Molecular Formula: C10H12ClN5O3
  • Molecular Weight: 285.7
  • Purity: ≥95%
Inquiry Now

Cladribine（Cat No.:I003531） is a medication that functions as an adenosine deaminase inhibitor. It is primarily used to treat two conditions: hairy cell leukemia (HCL) and multiple sclerosis (MS). In HCL, cladribine works by suppressing the production of abnormal white blood cells. In MS, it modulates the immune system to reduce the frequency of relapses. Cladribine is available in oral and injectable forms, and its use requires careful monitoring due to potential side effects, particularly effects on the immune system and bone marrow suppression.

Catalog Number I003531
CAS Number 4291-63-8
Molecular Formula

C10H12ClN5O3

Purity 95%
Target DNA Synthesis
Solubility DMSO: ≥ 48 mg/mL
Storage -20°C
IUPAC Name (2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol
InChI InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
InChIKey PTOAARAWEBMLNO-KVQBGUIXSA-N
SMILES C1C(C(OC1N2C=NC3=C(N=C(N=C32)Cl)N)CO)O
Reference

</br>1:A single center experience: rituximab plus cladribine is an effective and safe first-line therapy for unresectable bronchial-associated lymphoid tissue lymphoma. Wei Z, Li J, Cheng Z, Yuan L, Liu P.J Thorac Dis. 2017 Apr;9(4):1081-1092. doi: 10.21037/jtd.2017.03.81. PMID: 28523163 </br>2:Determination and quantification of intracellular fludarabine triphosphate, cladribine triphosphate and clofarabine triphosphate by LC-MS/MS in human cancer cells. Puy JY, Jordheim LP, Cros-Perrial E, Dumontet C, Peyrottes S, Lefebvre-Tournier I.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:101-110. doi: 10.1016/j.jchromb.2017.03.024. Epub 2017 Mar 24. PMID: 28415014 </br>3:Purpuric exanthema in a patient with hairy cell leukemia treated with cladribine and allopurinol. Espinosa Lara P, Quirós Redondo V, Aguado Lobo M, Jiménez-Reyes J.Ann Hematol. 2017 Apr 8. doi: 10.1007/s00277-017-2992-z. [Epub ahead of print] No abstract available. PMID: 28391438 </br>4:Population Pharmacokinetics of Cladribine in Patients with Multiple Sclerosis. Savic RM, Novakovic AM, Ekblom M, Munafo A, Karlsson MO.Clin Pharmacokinet. 2017 Mar 2. doi: 10.1007/s40262-017-0516-6. [Epub ahead of print] PMID: 28255849 </br>5:Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease. Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS.JAMA Oncol. 2017 Mar 2. doi: 10.1001/jamaoncol.2017.0041. [Epub ahead of print] PMID: 28253394 </br>6:Successful treatment of histiocytic sarcoma with cladribine and high-dose cytosine arabinoside in a child. Iwabuchi H, Kawashima H, Umezu H, Takachi T, Imamura M, Saitoh A, Ogose A, Imai C.Int J Hematol. 2017 Feb 28. doi: 10.1007/s12185-017-2202-8. [Epub ahead of print] PMID: 28247189 </br>7:Efficacy and Toxicity of Induction Therapy with Cladribine, Idarubicin, and Cytarabine (IAC) for Acute Myeloid Leukemia. Woelich SK, Braun JT, Schoen MW, Ramlal R, Freter CE, Petruska PJ, Lionberger JM.Anticancer Res. 2017 Feb;37(2):713-717. PMID: 28179321 </br>8:Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets. De Stefano N, Giorgio A, Battaglini M, De Leucio A, Hicking C, Dangond F, Giovannoni G, Sormani MP.Mult Scler. 2017 Jan 1:1352458517690269. doi: 10.1177/1352458517690269. [Epub ahead of print] PMID: 28140753 </br>9:Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial. Pluta A, Robak T, Wrzesien-Kus A, Katarzyna Budziszewska B, Sulek K, Wawrzyniak E, Czemerska M, Zwolinska M, Golos A, Holowiecka-Goral A, Kyrcz-Krzemien S, Piszcz J, Kloczko J, Mordak-Domagala M, Lange A, Razny M, Madry K, Wiktor-Jedrzejczak W, Grosicki S, Butrym A, Kuliczkowski K, Warzocha K, Holowiecki J, Giebel S, Szydlo R, Wierzbowska A.Am J Hematol. 2017 Apr;92(4):359-366. doi: 10.1002/ajh.24654. Epub 2017 Feb 13. PMID: 28103640 </br>10:Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. Alstadhaug KB, Fykse Halstensen R, Odeh F.J Clin Virol. 2017 Mar;88:17-20. doi: 10.1016/j.jcv.2016.12.005. Epub 2016 Dec 14. PMID: 28095350

Request a Quote

Contact Us at MuseChem

We are committed to providing you with reliable, cost-effective solutions for your chemical needs, while ensuring your safety and comfort. Our team of experts is always available to answer your questions and help you navigate the complexities of the chemical industry.

Whether you're looking for a specific product or need help with a custom synthesis project, we're here to help you discover a new world of chemical possibilities. Contact us today to learn more about how we can assist you with all of your chemical needs.

Our goal is to make the process of ordering chemicals as seamless and hassle-free as possible. Let us know how we can assist you, and we'll get back to you as soon as possible. We look forward to hearing from you!